Harbin Medisan Pharmaceutical Co Ltd

002900.CS▼

Harbin Sanlian Pharmaceutical's 2026 interim net loss reaches 44.19 million yuan

Harbin Sanlian Pharmaceutical released its 2026 interim report. Total operating revenue was 429 million yuan, net profit attributable to the parent company was a loss of 44.19 million yuan, and net cash inflow from operating activities was 68.63 million yuan. The company's latest asset-liability ratio was 45.93 percent, up 2.22 percentage points from the same period last year. Gross margin was 37.65 percent, down 3.23 percentage points from the previous quarter and down 4.91 percentage points from the same period last year. Return on equity was negative 2.56 percent, and diluted earnings per share was negative 0.14 yuan. The company had 29,900 shareholders, and the top ten shareholders held 67.61 percent of total share capital.

002900.CS ▼

Jiemian·10hRead more ▾

Artificial Intelligence▲impact 4

WuXi AppTec hits limit-up in a straight line; innovative drugs, computing power leasing, and nuclear power sectors rally together

On August 4, major A-share indices opened collectively higher. The innovative drug concept continued to climb, with the CXO segment leading the gains. WuXi AppTec surged in a straight line to hit its daily limit-up, and Asymchem, Luoxin Pharmaceuticals, Jimin Health, and Harbin Medisan also hit limit-up. In terms of news, WuXi AppTec released its 2026 half-year report, with first-half revenue of 28.9 billion yuan, up 38.9 percent year-on-year, and attributable net profit exceeding 10 billion yuan for the first time in a first half, reaching 11.08 billion yuan, up 29.43 percent year-on-year. The company raised its full-year 2026 performance guidance across the board, lifting expected total revenue from a range of 51.3 billion to 53 billion yuan to a range of 58.5 billion to 60.5 billion yuan. The computing power leasing concept was repeatedly active, with QingCloud Technologies hitting the 20 percent limit-up and Meili Cloud achieving a three-day winning streak. Data from the China Academy of Information and Communications Technology showed that domestic AI computing power demand surged 417 percent year-on-year in the first quarter of 2026, while effective supply grew only 128 percent, widening the supply-demand gap. The nuclear power sector also strengthened, with LBT hitting a two-day winning streak. In terms of news, the National Development and Reform Commission and the National Energy Administration issued the 15th Five-Year Plan for New Power System Construction, proposing to promote large-scale nuclear power construction, with installed nuclear power capacity reaching approximately 110 million kilowatts by 2030.

603259.CG ▲002793.CS ▲002821.CS ▲002900.CS ▲

Artificial Intelligence ▲Energy Transition & Power Demand ▲Biotech & Genomic Medicine ▲

证券时报·23dRead more ▾

002900.CS▼

Harbin Sanlian expects first-half 2026 loss of 38 million to 48 million yuan

Harbin Sanlian has released its earnings forecast, expecting a net loss attributable to the parent company of 38 million to 48 million yuan for the first half of 2026, compared with a loss of 92.3904 million yuan in the same period last year. The company also expects to achieve operating revenue of 429 million yuan, a net loss excluding non-recurring items of 47 million to 57 million yuan, and a basic loss per share of 0.12 to 0.15 yuan. The announcement stated that due to the impact of the national centralized drug procurement policy and intense competition in some non-procurement formulation markets, product prices are sluggish, while fixed costs are relatively rigid, making it difficult for gross profit to cover period expenses, which is the direct cause of the negative net profit. In addition, the fair value of the company's investment in the Hong Kong-listed SSY Group continued to decline, with a fair value change loss of 9.7902 million yuan during the reporting period.

002900.CS ▼2005.HK ▼

中国证券报·44dRead more ▾